Neel R. Sodha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neel R. Sodha has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Edward L. Snyder
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
2 shared publications - Gregory A. Nuttall
Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota
2 shared publications - Ian James Welsby
Duke University
2 shared publications - J. Peter R. Pelletier
Department of Transfusion Services, University of Florida, Gainesville, Florida
2 shared publications - James D. Gorham
Department of Pathology University of Virginia Health Charlottesville Virginia USA
2 shared publications - John Steven McNeil
Department of Anesthesiology, University of Virginia School of Medicine, Charlottesville, Virginia
2 shared publications
Latest Publications
- Open Access
- 12 August 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 143 (5) , 1196-1210
Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Background: Transfusion has a persistent low risk of transfusion-transmitted infection and transfusion-associated graft- versus -host disease that may be addressed using pathogen reduction. The Red Cell Pathogen Inactivation (ReCePI) trial tested whether amustaline/glutathione pathogen-reduced red cells are noninferior to conventional transfusions for support of acute surgical blood loss. Methods: A phase 3, double-blinded, noninferiority trial randomized cardiac or thoracic–aorta surgery patients with increased risk of red cell transfusion to receive pathogen-reduced or conventional red cells during and for 7 days postsurgery. The primary endpoint was the proportion of patients with acute kidney injury (AKI), which is defined as an increase from baseline of greater than or equal to 0.3 mg/dl serum creatinine within 48 h of surgery. Noninferiority was claimed if the upper bound 95% CI of the treatment difference was less than half (50%) of the observed conventional arm incidence. Adverse events and treatment-emergent red cell antibodies were assessed for 28 and 75 days, respectively. Results: A total of 581 subjects were randomized, and 321 (55%) were transfused with study red cells. Transfused subjects in both arms had similar baseline demographics, medical histories, hemoglobin levels, and surgical procedures. Hemoglobin day 3 nadir levels (8.6 g/dl [7.8 to 9.2] in the pathogen-reduced arm; 8.4 g/dl [7.8 to 9.3] in the conventional arm; P = 0.52) were comparable. Incidence of AKI by 48 h was 46 of 157 (29.3%) in the pathogen-reduced arm and 45 of 161 (28.0%) in the conventional arm (treatment difference, 0.7%; 95% CI, −8.9 to 10.4%; noninferiority margin, 14.0%; P = 0.001 for noninferiority). AKI within 7 days by Kidney Disease Improving Global Outcomes staging criteria was not different (59 of 159 [37.1%] in the pathogen-reduced arm; 55 of 162 [34.0%] in the conventional arm; P = 0.53), but stage III was more common in the pathogen-reduced arm (pathogen-reduced arm, 15 of 159 [9.4%]; conventional arm, 7 of 162 [4.3%]; P = 0.075). Of 159 pathogen-reduced red cell recipients, 5 (3.1%) developed specific, low-titer antibodies without evidence of hemolysis. Conclusions: The incidence of AKI in recipients of pathogen-reduced red cells was noninferior to conventional red cell transfusion. Treatment-emergent antibodies were uncommon and not clinically significant.
- 12 August 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 143 (5) , 1196-1210
Open AccessTransfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Background: Transfusion has a persistent low risk of transfusion-transmitted infection and transfusion-associated graft- versus -host disease that may be addressed using pathogen reduction. The Red Cell Pathogen Inactivation (ReCePI) trial tested whether amustaline/glutathione pathogen-reduced red cells are noninferior to conventional transfusions for support of acute surgical blood loss. Methods: A phase 3, double-blinded, noninferiority trial randomized cardiac or thoracic–aorta surgery patients with increased risk of red cell transfusion to receive pathogen-reduced or conventional red cells during and for 7 days postsurgery. The primary endpoint was the proportion of patients with acute kidney injury (AKI), which is defined as an increase from baseline of greater than or equal to 0.3 mg/dl serum creatinine within 48 h of surgery. Noninferiority was claimed if the upper bound 95% CI of the treatment difference was less than half (50%) of the observed conventional arm incidence. Adverse events and treatment-emergent red cell antibodies were assessed for 28 and 75 days, respectively. Results: A total of 581 subjects were randomized, and 321 (55%) were transfused with study red cells. Transfused subjects in both arms had similar baseline demographics, medical histories, hemoglobin levels, and surgical procedures. Hemoglobin day 3 nadir levels (8.6 g/dl [7.8 to 9.2] in the pathogen-reduced arm; 8.4 g/dl [7.8 to 9.3] in the conventional arm; P = 0.52) were comparable. Incidence of AKI by 48 h was 46 of 157 (29.3%) in the pathogen-reduced arm and 45 of 161 (28.0%) in the conventional arm (treatment difference, 0.7%; 95% CI, −8.9 to 10.4%; noninferiority margin, 14.0%; P = 0.001 for noninferiority). AKI within 7 days by Kidney Disease Improving Global Outcomes staging criteria was not different (59 of 159 [37.1%] in the pathogen-reduced arm; 55 of 162 [34.0%] in the conventional arm; P = 0.53), but stage III was more common in the pathogen-reduced arm (pathogen-reduced arm, 15 of 159 [9.4%]; conventional arm, 7 of 162 [4.3%]; P = 0.075). Of 159 pathogen-reduced red cell recipients, 5 (3.1%) developed specific, low-titer antibodies without evidence of hemolysis. Conclusions: The incidence of AKI in recipients of pathogen-reduced red cells was noninferior to conventional red cell transfusion. Treatment-emergent antibodies were uncommon and not clinically significant.
- Open Access
- 16 November 2023
- Published by Springer Nature in Research Square
Evaluation of the Efficacy & Safety of Amustaline/Glutathione Pathogen Reduced RBCs in Complex Cardiac Surgery: the Red Cell Pathogen Inactivation (ReCePI) Study - Protocol for a Phase 3, Randomized, Controlled Trial
Background Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from bacteria, emerging viruses, pathogens for which testing is not performed and from residual donor leukocytes. Amustaline (S-303)/glutathione (GSH) treatment pathogen reduction technology is designed to inactivate a broad spectrum of infectious agents and leucocytes in RBC concentrates. The ReCePI study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of pathogen reduced RBCs transfused for acute anemia in CVS compared to conventional RBCs, and to assess the clinical significance of treatment-emergent RBC antibodies. Methods ReCePI is a prospective, multicenter, randomized, double-blinded, active-controlled, paralleldesign, non-inferiority study. Eligible subjects will be randomized up to 7 days before surgery to receive either leukoreduced Test (pathogen reduced) or Control (conventional) RBCs from surgery up to Day 7 post-surgery. The primary efficacy endpoint is the proportion of patients transfused with at least one study transfusion with an acute kidney injury (AKI) diagnosis defined as any increased serum creatinine (sCr) level ≥0.3 mg/dL (or 26.5 µmol/L) from presurgery baseline within 48±4 hours of the end of surgery. The primary safety endpoints are the proportion of patients with any treatment-emergent adverse events (TEAEs) related to study RBC transfusion through 28 days, and the proportion of patients with treatment-emergent antibodies with confirmed specificity to pathogen reduced RBCs through 75 days after the last study transfusion. With ≥292 evaluable, transfused patients (>146 per arm), the study has 80% power to demonstrate non-inferiority, defined as a Test group AKI incidence increase of no more than 50% of the Control group rate, assuming a Control incidence of 30%. Discussion RBCs are transfused to prevent tissue hypoxia caused by surgery-induced bleeding and anemia. AKI is a sensitive indicator of renal hypoxia and a novel endpoint for assessing RBC efficacy. The ReCePI study is intended to demonstrate the non-inferiority of pathogen reduced RBCs to conventional RBCs in the support of renal tissue oxygenation due to acute anemia and to characterize the incidence of treatment-related antibodies to RBC.
- 16 November 2023
- Published by Springer Nature in Research Square
Open AccessEvaluation of the Efficacy & Safety of Amustaline/Glutathione Pathogen Reduced RBCs in Complex Cardiac Surgery: the Red Cell Pathogen Inactivation (ReCePI) Study - Protocol for a Phase 3, Randomized, Controlled Trial
Background Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from bacteria, emerging viruses, pathogens for which testing is not performed and from residual donor leukocytes. Amustaline (S-303)/glutathione (GSH) treatment pathogen reduction technology is designed to inactivate a broad spectrum of infectious agents and leucocytes in RBC concentrates. The ReCePI study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of pathogen reduced RBCs transfused for acute anemia in CVS compared to conventional RBCs, and to assess the clinical significance of treatment-emergent RBC antibodies. Methods ReCePI is a prospective, multicenter, randomized, double-blinded, active-controlled, paralleldesign, non-inferiority study. Eligible subjects will be randomized up to 7 days before surgery to receive either leukoreduced Test (pathogen reduced) or Control (conventional) RBCs from surgery up to Day 7 post-surgery. The primary efficacy endpoint is the proportion of patients transfused with at least one study transfusion with an acute kidney injury (AKI) diagnosis defined as any increased serum creatinine (sCr) level ≥0.3 mg/dL (or 26.5 µmol/L) from presurgery baseline within 48±4 hours of the end of surgery. The primary safety endpoints are the proportion of patients with any treatment-emergent adverse events (TEAEs) related to study RBC transfusion through 28 days, and the proportion of patients with treatment-emergent antibodies with confirmed specificity to pathogen reduced RBCs through 75 days after the last study transfusion. With ≥292 evaluable, transfused patients (>146 per arm), the study has 80% power to demonstrate non-inferiority, defined as a Test group AKI incidence increase of no more than 50% of the Control group rate, assuming a Control incidence of 30%. Discussion RBCs are transfused to prevent tissue hypoxia caused by surgery-induced bleeding and anemia. AKI is a sensitive indicator of renal hypoxia and a novel endpoint for assessing RBC efficacy. The ReCePI study is intended to demonstrate the non-inferiority of pathogen reduced RBCs to conventional RBCs in the support of renal tissue oxygenation due to acute anemia and to characterize the incidence of treatment-related antibodies to RBC.
- 1 September 2023
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 166 (3) , 713-714
Commentary: Biomechanics of the aorta: Insight into aortic pathology
- 1 September 2023
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 166 (3) , 713-714
Commentary: Biomechanics of the aorta: Insight into aortic pathology
- 3 September 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (3) , e9-e12
Left Ventricular Septal Avulsion in the Setting of Blunt Cardiac Injury
- 3 September 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (3) , e9-e12
Left Ventricular Septal Avulsion in the Setting of Blunt Cardiac Injury
- Open Access
- 19 April 2022
- Published by Elsevier in JTCVS Open
- Vol. 10, 111-112
Commentary: Contraventional wisdom: Primary management of lower-extremity malperfusion syndrome prior to ascending aortic repair in acute type A aortic dissection
- 19 April 2022
- Published by Elsevier in JTCVS Open
- Vol. 10, 111-112
Open AccessCommentary: Contraventional wisdom: Primary management of lower-extremity malperfusion syndrome prior to ascending aortic repair in acute type A aortic dissection
- 1 January 2022
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 34 (1) , 41-42
Commentary: Of Mice to Men: Mitigating Spinal Cord Injury During Complex Thoracic Aortic Surgery
- 1 January 2022
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 34 (1) , 41-42
Commentary: Of Mice to Men: Mitigating Spinal Cord Injury During Complex Thoracic Aortic Surgery
- 1 January 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 163 (1) , 25-26
Commentary: Spinal cord ischemia following aortic surgery: Survey says?
- 1 January 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 163 (1) , 25-26
Commentary: Spinal cord ischemia following aortic surgery: Survey says?
- 27 October 2021
- Published by Springer Nature
- p. 237-248
Aortic Intramural Hematoma
- Open Access
- 1 January 2021
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 33 (3) , 733-734
Commentary: Distension Kills: Venting the Left Ventricle During Venoarterial ECMO Support
- 1 January 2021
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 33 (3) , 733-734
Open AccessCommentary: Distension Kills: Venting the Left Ventricle During Venoarterial ECMO Support